Search Articles
WILMINGTON, Del. — Shareholders say in a federal class action that directors are selling Raptor Pharmaceutical Corp. too cheaply through an unfair process to Horizon Pharma PLC and Misneach Corp., for $9 a share or $800 million.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.